 |
 |
Linda J Herman wrote: > .... There are 5 other priority areas identified in the report, in > addition to stem cell research. What do you think about these? > > * Medical and Surgical Therapeutics Research > * Genetic Epidemiology and Gene Expression and Analysis > * Attracting Researchers to Parkinson's Disease > * Modes of Cooperation with the Private Sector > * Communicating with the Scientific Community and the Public In general the report as well as the research agenda as a whole are great news. It's wonderful to know that there is such committment and cooperation. These are exciting times. The priority items mentioned are only some those in the research agenda. Why are just these items to "receive the highest priority in the coming weeks"? I guess you had to be at the meeting. I was glad to see the following: > One area of special concern and opportunity is the non-motor > aspects of Parkinson's disease, including depression, cognitive > problems, sleep problems and autonomic disturbances. It's becoming clear that PD is much more than a movement disorder. > Tracking progress of the Research Agenda and communicating the > needs, opportunities, and ongoing activities with the scientific > and lay communities are essential. NINDS is developing a web based > program to chart and communicate progress and activities relevant > to the Research Agenda that will serve as a model for many future > NINDS efforts. I hope this will include the commercial research as well. I searched the NINDS and NIH web sites for "neuroimmunophilins", the hot new Amgen product, and found only the one reference - in the PD research agenda. No mention of Amgen or Guilford anywhere. It would sure be handy to have one place to go to that summarizes all the research, giving a brief description and status, with links to other sites for more details. Phil Tompkins